21-123 Phase I
A Phase 1b Sequential Open Label Dose Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects with Beta Thalassemia Intermedia (View details on clinicaltrial.gov)
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
A Phase 1b Sequential Open Label Dose Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects with Beta Thalassemia Intermedia (View details on clinicaltrial.gov)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia (View details on clinicaltrial.gov)
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (View details on clinicaltrial.gov)
A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer (View details on clinicaltrial.gov)
A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) (View details on clinicaltrial.gov)
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura (View details on clinicaltrial.gov)
ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX (View details on clinicaltrial.gov)
Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion Dependent Alpha- or Beta-Thalassemia (ENERGIZE) (View details on clinicaltrial.gov)
RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer (View details on clinicaltrial.gov)